Area of research
Cardiology and Cardiovascular Medicine · Surgery
Research interest
Research interests include Coronary Interventions and Diagnostics, Acute Myocardial Infarction Research, Antiplatelet Therapy and Cardiovascular Diseases, and Cardiac Imaging and Diagnostics.
Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trial
Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention
Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: primary results from the AVIATOR 2 international registry
Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI
Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR
Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI
Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI
Ticagrelor With or Without Aspirin After Complex PCI
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS
Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention
Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention
Ticagrelor with or without Aspirin in High-Risk Patients after PCI
Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age
Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk
Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry
Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry)
Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes
Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents
Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry
Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry)
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents
Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention
Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents
Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry